{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:06:57Z","timestamp":1787026017608,"version":"build-2736575974"},"reference-count":45,"publisher":"Tottori University Faculty of Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Yonago Acta Med."],"published-print":{"date-parts":[[2018]]},"DOI":"10.33160\/yam.2018.12.003","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T18:49:33Z","timestamp":1552589373000},"page":"204-212","source":"Crossref","is-referenced-by-count":24,"title":["Early Intensive Nutrition Intervention with Dietary Counseling andOral Nutrition Supplement Prevents Weight Loss in Patients with Advanced LungCancer Receiving Chemotherapy: A Clinical Prospective Study"],"prefix":"10.33160","volume":"61","author":[{"given":"Natsumi","family":"Tanaka","sequence":"first","affiliation":[{"name":"Division of Medical Oncology and Molecular Respirology,Department of Multidisciplinary Internal Medicine, School of Medicine,Tottori University Faculty of Medicine, Yonago 683-8503,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Takeda","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Molecular Respirology,Department of Multidisciplinary Internal Medicine, School of Medicine,Tottori University Faculty of Medicine, Yonago 683-8503,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Kawasaki","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Molecular Respirology,Department of Multidisciplinary Internal Medicine, School of Medicine,Tottori University Faculty of Medicine, Yonago 683-8503,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Yamane","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Molecular Respirology,Department of Multidisciplinary Internal Medicine, School of Medicine,Tottori University Faculty of Medicine, Yonago 683-8503,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Teruya","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Molecular Respirology,Department of Multidisciplinary Internal Medicine, School of Medicine,Tottori University Faculty of Medicine, Yonago 683-8503,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kodani","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Molecular Respirology,Department of Multidisciplinary Internal Medicine, School of Medicine,Tottori University Faculty of Medicine, Yonago 683-8503,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Igishi","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Molecular Respirology,Department of Multidisciplinary Internal Medicine, School of Medicine,Tottori University Faculty of Medicine, Yonago 683-8503,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Yamasaki","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Molecular Respirology,Department of Multidisciplinary Internal Medicine, School of Medicine,Tottori University Faculty of Medicine, Yonago 683-8503,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18656","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Dewys WD, Begg C,Lavin PT, Band PR, Bennett JM, Bertino JR, et al. Prognostic effect of weightloss prior to chemotherapy in cancer patients. Eastern Cooperative OncologyGroup. Am J Med. 1980;69:491-7. PMID: 7424938","DOI":"10.1016\/S0149-2918(05)80001-3"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Laviano A, MeguidMM. Nutritional issues in cancer management. Nutrition. 1996;12:358-71. ,PMID:8875522","DOI":"10.1016\/S0899-9007(96)80061-X"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Bennani-Baiti N,Davis MP. Cytokines and cancer anorexia cachexia syndrome. Am J Hosp PalliatCare. 2008;25:407-11. PMID: 18403577","DOI":"10.1177\/1049909108315518"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Arends J, BachmannP, Baracos V, Barthelemy N, Bertz H, Bozzetti F, et al. ESPEN guidelines onnutrition in cancer patients. Clinical nutrition (Edinburgh, Scotland).2017;36:11-48. PMID: 27637832","DOI":"10.1016\/j.clnu.2016.07.015"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Lorusso V,Giampaglia M, Petrucelli L, Saracino V, Perrone T, Gnoni A. Antiemetic efficacyof single-dose palonosetron and dexamethasone in patients receiving multiplecycles of multiple day-based chemotherapy. Supportive care in cancer : officialjournal of the Multinational Association of Supportive Care in Cancer.2012;20:3241-6. PMID: 22534864","DOI":"10.1007\/s00520-012-1469-9"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Haiderali A,Menditto L, Good M, Teitelbaum A, Wegner J. Impact on daily functioning andindirect\/direct costs associated with chemotherapy-induced nausea and vomiting(CINV) in a U.S. population. Supportive care in cancer : official journal of theMultinational Association of Supportive Care in Cancer. 2011;19:843-51. PMID: 20532923","DOI":"10.1007\/s00520-010-0915-9"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Bloechl-Daum B,Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continueto reduce patients\u2019 quality of life after highly and moderately emetogenicchemotherapy despite antiemetic treatment. J Clin Oncol. 2006;24:4472-8. PMID: 16983116","DOI":"10.1200\/JCO.2006.05.6382"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 de van der SchuerenMAE, Laviano A, Blanchard H, Jourdan M, Arends J, Baracos VE. Systematic reviewand meta-analysis of the evidence for oral nutritional intervention onnutritional and clinical outcomes during chemo(radio)therapy: current evidenceand guidance for design of future trials. Ann Oncol. 2018;29:1141-53. PMID: 29788170","DOI":"10.1093\/annonc\/mdy114"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Bourdel-MarchassonI, Blanc-Bisson C, Doussau A, Germain C, Blanc JF, Dauba J, et al. Nutritionaladvice in older patients at risk of malnutrition during treatment forchemotherapy: a two-year randomized controlled trial. PLoS One. 2014;9:e108687.PMID: 25265392","DOI":"10.1371\/journal.pone.0108687"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Baldwin C, Spiro A,McGough C, Norman AR, Gillbanks A, Thomas K, et al. Simple nutritionalintervention in patients with advanced cancers of the gastrointestinal tract,non-small cell lung cancers or mesothelioma and weight loss receivingchemotherapy: a randomised controlled trial. J Hum Nutr Diet. 2011;24:431-40.PMID: 21733143","DOI":"10.1111\/j.1365-277X.2011.01189.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Elkort RJ, Baker FL,Vitale JJ, Cordano A. Long-term nutritional support as an adjunct tochemotherapy for breast cancer. JPEN J Parenter Enteral Nutr. 1981;5:385-90.PMID: 6796711","DOI":"10.1177\/0148607181005005385"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Chawla SP, GrunbergSM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, et al. Establishing the doseof the oral NK1 antagonist aprepitant for the prevention of chemotherapy-inducednausea and vomiting. Cancer. 2003;97:2290-300. PMID: 12712486","DOI":"10.1002\/cncr.11320"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Hesketh PJ, GrunbergSM, Gralla RJ, Warr DG, Roila F, de Wit R, et al. The oral neurokinin-1antagonist aprepitant for the prevention of chemotherapy-induced nausea andvomiting: a multinational, randomized, double-blind, placebo-controlled trial inpatients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.J Clin Oncol.. 2003;21:4112-9. PMID: 14559886","DOI":"10.1200\/JCO.2003.01.095"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Poli-Bigelli S,Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, et al.Addition of the neurokinin 1 receptor antagonist aprepitant to standardantiemetic therapy improves control of chemotherapy-induced nausea and vomiting.Results from a randomized, double-blind, placebo-controlled trial in LatinAmerica. Cancer. 2003;97:3090-8. PMID: 12784346","DOI":"10.1002\/cncr.11433"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Takahashi T, HoshiE, Takagi M, Katsumata N, Kawahara M, Eguchi K, et al. Multicenter, phase II,placebo-controlled, double-blind, randomized study of aprepitant in Japanesepatients receiving high-dose cisplatin. Cancer Sci. 2010;101:2455-61. PMID: 20718754","DOI":"10.1111\/j.1349-7006.2010.01689.x"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Takeuchi H, Saeki T,Aiba K, Tamura K, Aogi K, Eguchi K, et al. Japanese Society of Clinical Oncologyclinical practice guidelines 2010 for antiemesis in oncology: executive summary.Int J Clin Oncol. 2016;21:1-12. PMID: 26081252","DOI":"10.1007\/s10147-015-0852-1"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Berger MJ, EttingerDS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, et al. NCCN GuidelinesInsights: Antiemesis, Version 2.2017. J Natl Compr Canc Netw. 2017;15:883-93.PMID: 28687576","DOI":"10.6004\/jnccn.2017.0117"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Roila F, MolassiotisA, Herrstedt J, Aapro M, Gralla RJ, Bruera E, et al. 2016 MASCC and ESMOguideline update for the prevention of chemotherapy- and radiotherapy-inducednausea and vomiting and of nausea and vomiting in advanced cancer patients. AnnOncol. 2016;27:v119-v33. PMID: 27664248","DOI":"10.1093\/annonc\/mdw270"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Hesketh PJ, Kris MG,Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: AmericanSociety of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol.2017;35:3240-61. PMID: 28837374","DOI":"10.1200\/JCO.2017.74.4789"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Harris JA, BenedictFG. A Biometric Study of Human Basal Metabolism. Proc Natl Acad Sci U S A.1918;4:370-3. PMID: 16576330","DOI":"10.1073\/pnas.4.12.370"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Long CL, Schaffel N,Geiger JW, Schiller WR, Blakemore WS. Metabolic response to injury and illness:estimation of energy and protein needs from indirect calorimetry and nitrogenbalance. JPEN J Parenter Enteral Nutr. 1979;3:452-6. PMID: 575168","DOI":"10.1177\/014860717900300609"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Takayanagi T, SasakiH, Kawashima A, Mizuochi Y, Hirate H, Sugiura T, et al. A new enteral diet,MHN-02, which contains abundant antioxidants and whey peptide, protects againstcarbon tetrachloride-induced hepatitis. JPEN J Parenter Enteral Nutr.2011;35:516-22. PMID: 21700967","DOI":"10.1177\/0148607110381599"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Brooks R EuroQol:the current state of play. Health Policy. 1996;37:53-72. PMID: 10158943","DOI":"10.1016\/0168-8510(96)00822-6"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Kobayashi S,Murakami K, Sasaki S, Okubo H, Hirota N, Notsu A, et al. Comparison of relativevalidity of food group intakes estimated by comprehensive and brief-typeself-administered diet history questionnaires against 16 d dietary records inJapanese adults. Public Health Nutr. 2011;14:1200-11. PMID: 21477414","DOI":"10.1017\/S1368980011000504"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Kobayashi S, HondaS, Murakami K, Sasaki S, Okubo H, Hirota N, et al. Both comprehensive and briefself-administered diet history questionnaires satisfactorily rank nutrientintakes in Japanese adults. J Epidemiol. 2012;22:151-9. PMID: 22343326","DOI":"10.2188\/jea.JE20110075"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Austin PC, StuartEA. Moving towards best practice when using inverse probability of treatmentweighting (IPTW) using the propensity score to estimate causal treatment effectsin observational studies. Stat Med. 2015;34:3661-79. PMID: 26238958","DOI":"10.1002\/sim.6607"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 World MedicalAssociation Declaration of Helsinki: ethical principles for medical researchinvolving human subjects. Jama. 2013;310:2191-4. PMID: 24141714","DOI":"10.1001\/jama.2013.281053"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Martin F, SantolariaF, Batista N, Milena A, Gonzalez-Reimers E, Brito MJ, et al. Cytokine levels(IL-6 and IFN-gamma), acute phase response and nutritional status as prognosticfactors in lung cancer. Cytokine. 1999;11:80-6. PMID: 10080883","DOI":"10.1006\/cyto.1998.0398"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Simons JP, ScholsAM, Buurman WA, Wouters EF. Weight loss and low body cell mass in males withlung cancer: relationship with systemic inflammation, acute-phase response,resting energy expenditure, and catabolic and anabolic hormones. Clin sci(Lond). 1999;97:215-23. PMID: 10409477","DOI":"10.1042\/cs0970215"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Finocchiaro C, SegreO, Fadda M, Monge T, Scigliano M, Schena M, et al. Effect of n-3 fatty acids onpatients with advanced lung cancer: a double-blind, placebo-controlled study.The British journal of nutrition. 2012;108:327-33. PMID: 22114792","DOI":"10.1017\/S0007114511005551"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Sanchez-Lara K,Turcott JG, Juarez-Hernandez E, Nunez-Valencia C, Villanueva G, Guevara P, etal. Effects of an oral nutritional supplement containing eicosapentaenoic acidon nutritional and clinical outcomes in patients with advanced non-small celllung cancer: randomised trial. Clinical nutrition (Edinburgh, Scotland).2014;33:1017-23. PMID: 24746976","DOI":"10.1016\/j.clnu.2014.03.006"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Bruera E, StrasserF, Palmer JL, Willey J, Calder K, Amyotte G, et al. Effect of fish oil onappetite and other symptoms in patients with advanced cancer andanorexia\/cachexia: a double-blind, placebo-controlled study. J Clin Oncol.2003;21:129-34. PMID: 12506181","DOI":"10.1200\/JCO.2003.01.101"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 van der Meij BS,Langius JA, Smit EF, Spreeuwenberg MD, von Blomberg BM, Heijboer AC, et al. Oralnutritional supplements containing (n-3) polyunsaturated fatty acids affect thenutritional status of patients with stage III non-small cell lung cancer duringmultimodality treatment. J Nutr. 2010;140:1774-80. PMID: 20739445","DOI":"10.3945\/jn.110.121202"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 de Aguiar PastoreSilva J, Emilia de Souza Fabre M, Waitzberg DL. Omega-3 supplements for patientsin chemotherapy and\/or radiotherapy: A systematic review. Clinical nutrition(Edinburgh, Scotland). 2015;34:359-66. PMID: 25907586","DOI":"10.1016\/j.clnu.2014.11.005"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Laviano A, Rianda S,Molfino A, Rossi Fanelli F. Omega-3 fatty acids in cancer. Curr Opin Clin NutrMetab Care. 2013;16:156-61. PMID: 23299701","DOI":"10.1097\/MCO.0b013e32835d2d99"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Wigmore SJ, FearonKC, Maingay JP, Ross JA. Down-regulation of the acute-phase response in patientswith pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediatedvia suppression of interleukin-6. Clin sci (Lond). 1997;92:215-21. ,PMID:9059324","DOI":"10.1042\/cs0920215"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Barber MD, McMillanDC, Preston T, Ross JA, Fearon KC. Metabolic response to feeding inweight-losing pancreatic cancer patients and its modulation by afish-oil-enriched nutritional supplement. Clin sci (Lond). 2000;98:389-99.PMID: 10731472","DOI":"10.1042\/cs0980389"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Barber MD, Ross JA,Preston T, Shenkin A, Fearon KC. Fish oil-enriched nutritional supplementattenuates progression of the acute-phase response in weight-losing patientswith advanced pancreatic cancer. J Nutr. 1999;129:1120-5. PMID: 10356075","DOI":"10.1093\/jn\/129.6.1120"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Wigmore SJ, BarberMD, Ross JA, Tisdale MJ, Fearon KC. Effect of oral eicosapentaenoic acid onweight loss in patients with pancreatic cancer. Nutr Cancer. 2000;36:177-84.PMID: 10890028","DOI":"10.1207\/S15327914NC3602_6"},{"key":"40","unstructured":"40 Fukuda Y. TheNational Health and Nutrition Survey in Japan, 2016 [Internet]. Ministry ofHealth, Labor and Welfare; [cited 2018 Aug 15]. Available from:https:\/\/www.mhlw.go.jp\/bunya\/kenkou\/eiyou\/dl\/h28-houkoku-04.pdf. Japanese."},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Trumbo P, SchlickerS, Yates AA, Poos M. Dietary reference intakes for energy, carbohydrate, fiber,fat, fatty acids, cholesterol, protein and amino acids. J Am Diet Assoc.2002;102:1621-30. PMID: 12449285","DOI":"10.1016\/S0002-8223(02)90346-9"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Martin L, BirdsellL, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia inthe age of obesity: skeletal muscle depletion is a powerful prognostic factor,independent of body mass index. J Clin Oncol. 2013;31:1539-47. PMID: 23530101","DOI":"10.1200\/JCO.2012.45.2722"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Meyerhardt JA,Giovannucci EL, Ogino S, Kirkner GJ, Chan AT, Willett W, et al. Physicalactivity and male colorectal cancer survival. Arch Intern Med. 2009;169:2102-8.PMID: 20008694","DOI":"10.1001\/archinternmed.2009.412"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Richman EL, KenfieldSA, Stampfer MJ, Paciorek A, Carroll PR, Chan JM. Physical activity afterdiagnosis and risk of prostate cancer progression: data from the cancer of theprostate strategic urologic research endeavor. Cancer Res. 2011;71:3889-95.PMID: 21610110","DOI":"10.1158\/0008-5472.CAN-10-3932"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Bade BC, Thomas DD,Scott JB, Silvestri GA. Increasing physical activity and exercise in lungcancer: reviewing safety, benefits, and application. J Thorac Oncol.2015;10:861-71. PMID: 25831230","DOI":"10.1097\/JTO.0000000000000536"}],"container-title":["Yonago Acta Medica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yam\/61\/4\/61_2018.12.003\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T10:47:06Z","timestamp":1574333226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yam\/61\/4\/61_2018.12.003\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.33160\/yam.2018.12.003","relation":{},"ISSN":["1346-8049"],"issn-type":[{"value":"1346-8049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}